AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Akari Therapeutics to Present at Webull Financial Corporate Connect Webinar Series
ByAinvest
Thursday, Aug 14, 2025 3:38 pm ET1min read
Akari Therapeutics will present at the Webull Financial Corporate Connect Webinar Series on August 19, 2025. CEO Abizer Gaslightwala will discuss the company's advancements in Antibody Drug Conjugates for cancer treatment. The virtual event runs from August 19-21, 2025, focusing on biotechnology and medical technology innovations. Akari Therapeutics is known for its novel payload, PH1, which targets the Trop2 receptor on cancer cells.
Akari Therapeutics, a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech virtual event. The company's President and CEO, Abizer Gaslightwala, will present on Tuesday, August 19, 2025, at 2:00 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025 [1].The presentation will highlight Akari Therapeutics' advancements in developing novel payload antibody drug conjugates (ADCs). The company's first novel payload, PH1, is a spliceosome modulator designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing modulator has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity [2].
Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls [2].
The Webull Financial Corporate Connect Webinar Series is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. The event will provide an opportunity for investors and financial professionals to learn more about Akari Therapeutics' innovative approach to cancer treatment and the potential of their lead candidate, AKTX-101 [1].
References:
[1] https://www.stocktitan.net/news/AKTX/akari-therapeutics-to-present-at-the-webull-financial-corporate-7uel0y6gzv3d.html
[2] https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-present-webull-financial-corporate-connect
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet